"Right now I have got my hands full. My goal is to help Lilly navigate through this tough patch," said John Lechleiter, who joined Lilly in 1979 as an organic chemist and became CEO in 2008.
Lechleiter ruled out acquisitions to plug the hole left by Zyprexa and pointed to Lilly's pipeline of potential medicines that were in the last stages of trials in the United States.
"You can't just order up a new menu item like it's McDonald's. It's a longer-term cycle. Investors understand that," he said.
Monday, November 14, 2011
Eli Lilly faces tough times with patent losses - Yahoo! News